Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus Story Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsReported by Nathan Reiff. Publication Date: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon's "Hidden" Company
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancers with dedicated mechanisms. Fortunately, a number of promising treatments have shown significant potential—and with that comes the possibility of sizable sales. Two smaller biotech companies are seeing notable share-price momentum thanks to their leading oncology medicines. Beyond potential clinical impact, these drugs could help the firms move beyond penny-stock or otherwise unstable status and toward long-term profitability. That said, these remain typical biotech investments: high-risk ventures that could deliver outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle I've worked for the CIA, personally met four US presidents, and spent 45 years studying the markets—calling Black Monday six weeks before it happened, predicting the fall of the Berlin Wall, and pinpointing the exact bottom in 2009. But what I'm about to share with you is the boldest prediction of my career. After meeting Elon Musk face-to-face at a private gathering of Wall Street elites and months of my own research, I'm now staking my reputation on one date: March 26, 2026. That's when I believe Elon will announce the SpaceX IPO—what Bloomberg is calling the biggest listing of all time. I have found an access code that lets you grab a pre-IPO stake before it happens, but in 72 hours, your window could close. Click here to see how to claim your SpaceX access code Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. That added to IOVA's year-to-date performance, which has more than doubled so far. Still, with a consensus price target of $8.88, Wall Street expects further upside—that target implies roughly 71% more gains from current levels. The main catalyst for Iovance's move is its lead drug, Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is gaining momentum both in sales and regulatory progress, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in U.S. peak sales. Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track Designation for the treatment of non-small cell lung cancer and is being evaluated for other indications. Iovance's outperformance this year was also supported by its Q4 2025 earnings report, issued in late February, which showed narrower-than-expected losses per share and $5 million in revenue. For the full year, revenue rose about 30% year-over-year. Iovance remains a small-cap biotech (about $2 billion) and is still treated cautiously by many analysts—roughly half of its dozen ratings are Hold or Sell. Significant risks remain: Amtagvi is a personalized therapy that is costly and complex to manufacture, which could limit Iovance's ability to generate profit even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) has pulled back about 20% in March, but its year-to-date performance dwarfs Iovance's: IBRX shares are up nearly 300% in 2026 alone. Analysts' price targets average $13.60, roughly 70% above the stock's current level even after the recent surge. ImmunityBio's primary growth driver is Anktiva, a treatment for specific types of bladder cancer. In February, shares spiked after the E.U. regulator granted the drug conditional marketing authorization—the latest in a series of approvals worldwide. Anktiva is fueling revenue growth, generating $113 million in sales last year, a roughly 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer types, and ImmunityBio is actively exploring additional indications. Despite the recent rally, IBRX remains speculative and risky. The company reported a full-year net loss of $351 million for 2025 as R&D expenses continue to mount. Analysts appear somewhat more bullish on ImmunityBio than on Iovance: six of seven covering the stock rate it a Buy or equivalent. | 
